-+ 0.00%
-+ 0.00%
-+ 0.00%

IBA, Framatome JV Partners with Telix for Astatine-211 Development in US

MT Newswires·10/19/2026 02:01:40
Listen to the news
02:01 AM EDT, 10/19/2026 (MT Newswires) -- Ekalia, a joint venture between Ion Beam Applications (IBAB.BR), or IBA, and Framatome, partnered with Telix Pharmaceuticals to advance the production of astatine-211, an alpha-emitting radioisotope with potential applications in targeted cancer therapies, in the US. Under the collaboration, Ekalia will tap into the Australia-based biotechnology company's radiopharmaceutical network and operational capabilities to develop its first production unit in the US, according to a Monday release. The first installation would be at Telix's Trevose facility in Pennsylvania, with the potential for further rollout across the network as demand develops. Telix will also benefit from secured access to a portion of the astatine-211 production capacity.